Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial

Disease Areas:
Cough
Device Types:
VitaloJAK

This randomized, double-blind, placebo-controlled crossover study evaluated the anti-tussive effect of SB-705498 in 21 patients with refractory chronic cough attending a specialist clinic. The co-primary endpoints were cough responses to inhaled capsaicin 2 hours post-dose and 24-hour cough frequency; secondary endpoints included cough severity, urge to cough, and CQLQ score. Cough was objectively measured using the Vitalograph VitaloJAK cough monitor.

chevron_right View Article

Talk to our team